Aaron Lorenzo
Follow-on biologics, changes to the patent system, new rules from the FDA and the prospect of a new party in the White House dominate the policy outlook for biotechs. Aaron Lorenzo reports.
Follow-on biologics, changes to the patent system, new rules from the FDA and the prospect of a new party in the White House dominate the policy outlook for biotechs. Aaron Lorenzo reports.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.